CagrisSema is a once weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising Long acting amylin analogues for the management : Current Opinion in Endocrinology, Diabetes & Obesity Cagrilintide: The Peptide That Makes You Forget About Food. I call it the silence between cravings. Cagrilintide is a long acting amylin analog which means it works alongside leptin and GLP 1 to Targeting the incretin system in obesity and type 2 diabetes mellitus Nature Reviews Endocrinology In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results The Obesity Wars of 2026 continue: Novo's Miss, Lilly's Supremacy, and the Quality of Weight Loss Pivot